FDA Approves New Oral Medication for High Cholesterol

The U.S. FDA has granted approval to Merck's Lipfendra, an oral PCSK9 inhibitor, for treating high cholesterol in adults, including those with heterozygous familial hypercholesterolemia. This once-daily tablet offers a new, non-injectable treatment option for patients managing elevated LDL-C levels. The approval marks a significant advancement in cholesterol management.